166 related articles for article (PubMed ID: 19693451)
1. Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
Igarashi N; Chou T; Hirose T; Imai Y; Ishiguro T; Nemoto K
Int J Hematol; 2009 Oct; 90(3):378-382. PubMed ID: 19693451
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
3. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Montefusco V; Spina F; Patriarca F; Offidani M; Bruno B; Montanari M; Mussetti A; Sperotto A; Scortechini I; Dodero A; Fanin R; Valagussa P; Corradini P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):424-8. PubMed ID: 23142330
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
6. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
Krüger WH; Kiefer T; Schüler F; Lotze C; Busemann C; Dölken G
Onkologie; 2007 Apr; 30(4):193-5. PubMed ID: 17396042
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
Hoevenaren IA; van Vulpen LF; Levenga H; Minnema MC; Raymakers R
Bone Marrow Transplant; 2011 Feb; 46(2):319-21. PubMed ID: 20305701
[No Abstract] [Full Text] [Related]
8. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
Michallet M; Sobh M; El-Cheikh J; Morisset S; Sirvent A; Reman O; Cornillon J; Tabrizi R; Milpied N; Harousseau JL; Labussière H; Nicolini FE; Attal M; Moreau P; Mohty M; Blaise D; Avet-Loiseau H
Exp Hematol; 2013 Dec; 41(12):1008-15. PubMed ID: 23994781
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C
Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009
[TBL] [Abstract][Full Text] [Related]
11. [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
Vokurka S
Klin Onkol; 2010; 23(4):242-4. PubMed ID: 20806822
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
[TBL] [Abstract][Full Text] [Related]
14. Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
Zhou X; Zhu J; Sun H; Shao L; Xu M; Guo H
Leuk Lymphoma; 2013 Jan; 54(1):209-11. PubMed ID: 22734810
[No Abstract] [Full Text] [Related]
15. True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations-Brief Report.
Hoffmann M; Banz Y; Halter J; Schoumans J; Tchinda J; Bacher U; Pabst T
Curr Oncol; 2024 Apr; 31(4):2067-2075. PubMed ID: 38668056
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
Sun K; Li M; Sayers TJ; Welniak LA; Murphy WJ
Blood; 2008 Aug; 112(4):1522-9. PubMed ID: 18539902
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
